Ignite Creation Date:
2024-05-06 @ 1:56 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04161495
Status:
COMPLETED
Last Update Posted:
2023-05-24
First Post:
2019-11-05
Brief Title:
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein Efanesoctocog Alfa BIVV001 in Patients With Severe Hemophilia A
Sponsor:
Bioverativ a Sanofi company
Organization:
Sanofi
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Factor VIII Deficiency |
Keywords: